{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:02:46Z","timestamp":1769878966693,"version":"3.49.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10620-020-06281-8","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T08:02:49Z","timestamp":1588924969000},"page":"1315-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost\u2013Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong"],"prefix":"10.1007","volume":"66","author":[{"given":"Man-Fung","family":"Yuen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze-Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby L.","family":"Corman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Y. K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsz K.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Puenpatom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"6281_CR1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"H Wang","year":"2016","unstructured":"Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459\u20131544.","journal-title":"Lancet"},{"key":"6281_CR2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/liv.13926","volume":"38","author":"YT Hui","year":"2018","unstructured":"Hui YT, Wong GLH, Fung JYY, et al. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int. 2018;38:1911\u20131919.","journal-title":"Liver Int"},{"key":"6281_CR3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418\u2013431.","journal-title":"Hepatology"},{"key":"6281_CR4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","volume":"35","author":"E Akhtar","year":"2015","unstructured":"Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35:30\u201336.","journal-title":"Liver Int"},{"key":"6281_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","volume":"15","author":"J Smith-Palmer","year":"2015","unstructured":"Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.","journal-title":"BMC Infect Dis"},{"key":"6281_CR6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2006.10.009","volume":"46","author":"HL Bonkovsky","year":"2007","unstructured":"Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420\u2013431.","journal-title":"J Hepatol"},{"key":"6281_CR7","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","volume":"150","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150:1599\u20131608.","journal-title":"Gastroenterology"},{"key":"6281_CR8","unstructured":"World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/206453\/WHO_HIV_2016.04_eng.pdf;jsessionid=4BD913237991690DE2A6A6FDE7DFD5A8?sequence=1. Accessed February 5, 2019."},{"key":"6281_CR9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","volume":"19","author":"F Poordad","year":"2012","unstructured":"Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19:449\u2013464.","journal-title":"J Viral Hepat"},{"key":"6281_CR10","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","volume":"348","author":"ER Feeney","year":"2014","unstructured":"Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308.","journal-title":"BMJ"},{"key":"6281_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","volume":"3","author":"AD Marshall","year":"2018","unstructured":"Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3:125\u2013133.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6281_CR12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jval.2017.05.003","volume":"20","author":"S Corman","year":"2017","unstructured":"Corman S, Elbasha EH, Michalopoulos SN, et al. Cost-utility of elbasvir\/grazoprevir in patients with chronic hepatitis C genotype 1 infection. Value Health. 2017;20:1110\u20131120.","journal-title":"Value Health"},{"key":"6281_CR13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2036.2003.01453.x","volume":"17","author":"M Buti","year":"2003","unstructured":"Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther. 2003;17:687\u2013694.","journal-title":"Aliment Pharmacol Ther"},{"key":"6281_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","volume":"290","author":"JA Salomon","year":"2003","unstructured":"Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228\u2013237.","journal-title":"JAMA"},{"key":"6281_CR15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","volume":"52","author":"U Siebert","year":"2003","unstructured":"Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425\u2013432.","journal-title":"Gut"},{"key":"6281_CR16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00019053-200422040-00004","volume":"22","author":"SD Sullivan","year":"2004","unstructured":"Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics. 2004;22:257\u2013265.","journal-title":"Pharmacoeconomics"},{"key":"6281_CR17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/hep.510300518","volume":"30","author":"ZM Younossi","year":"1999","unstructured":"Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318\u20131324.","journal-title":"Hepatology"},{"key":"6281_CR18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","volume":"16","author":"J Chhatwal","year":"2013","unstructured":"Chhatwal J, Ferrante SA, Brass C, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16:973\u2013986.","journal-title":"Value Health"},{"key":"6281_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40258-012-0007-8","volume":"11","author":"EH Elbasha","year":"2013","unstructured":"Elbasha EH, Chhatwal J, Ferrante SA, et al. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy. 2013;11:65\u201378.","journal-title":"Appl Health Econ Health Policy"},{"key":"6281_CR20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2334-13-190","volume":"13","author":"SA Ferrante","year":"2013","unstructured":"Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013;13:190.","journal-title":"BMC Infect Dis"},{"key":"6281_CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/apt.13882","volume":"45","author":"EH Elbasha","year":"2017","unstructured":"Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naive and treatment-experienced) subjects treated with all-oral elbasvir\/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2017;45:455\u2013467.","journal-title":"Aliment Pharmacol Ther"},{"key":"6281_CR22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force\u20133. Value Health. 2012;15:812\u2013820.","journal-title":"Value Health."},{"key":"6281_CR23","doi-asserted-by":"crossref","first-page":"e0185609","DOI":"10.1371\/journal.pone.0185609","volume":"12","author":"SLG Chen Yi Mei","year":"2017","unstructured":"Chen Yi Mei SLG, Thompson AJ, Christensen B, et al. Sustained virological response halts fibrosis progression: a long-term follow-up study of people with chronic hepatitis C infection. PLoS ONE. 2017;12:e0185609.","journal-title":"PLoS ONE"},{"key":"6281_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2014.03.012","volume":"107","author":"YA Lee","year":"2014","unstructured":"Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res. 2014;107:23\u201330.","journal-title":"Antiviral Res"},{"key":"6281_CR25","first-page":"e41077","volume":"16","author":"SM Alavian","year":"2016","unstructured":"Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based treatment regimens for hepatitis C virus infection: a systematic review and meta-analysis. Hepat Mon. 2016;16:e41077.","journal-title":"Hepat Mon"},{"key":"6281_CR26","unstructured":"ZEPATIER package insert, 26 June 2019 update. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zepatier#product-information-section. Accessed February 25, 2020."},{"key":"6281_CR27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u2013982.","journal-title":"N Engl J Med"},{"key":"6281_CR28","unstructured":"VIEKIRAX package insert, 14 November 2019 update. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/viekirax-epar-product-information_en.pdf. Accessed February 25, 2020."},{"key":"6281_CR29","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373:2599\u20132607.","journal-title":"N Engl J Med"},{"key":"6281_CR30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, et al. Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354\u2013369.","journal-title":"N Engl J Med"},{"key":"6281_CR31","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062\u20131068.","journal-title":"Lancet Infect Dis"},{"key":"6281_CR32","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597\u20131605.","journal-title":"Lancet"},{"key":"6281_CR33","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u20131493.","journal-title":"N Engl J Med"},{"key":"6281_CR34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","volume":"56","author":"R D\u2019Ambrosio","year":"2012","unstructured":"D\u2019Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532\u2013543.","journal-title":"Hepatology"},{"key":"6281_CR35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463\u2013472.","journal-title":"Gastroenterology"},{"key":"6281_CR36","first-page":"66","volume":"92","author":"P Gentilini","year":"1997","unstructured":"Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;92:66\u201372.","journal-title":"Am J Gastroenterol"},{"key":"6281_CR37","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.510270535","volume":"27","author":"L Serfaty","year":"1998","unstructured":"Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435\u20131440.","journal-title":"Hepatology"},{"key":"6281_CR38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/gut.2003.020263","volume":"53","author":"L Benvegnu","year":"2004","unstructured":"Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744\u2013749.","journal-title":"Gut"},{"key":"6281_CR39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","volume":"43","author":"A Sangiovanni","year":"2006","unstructured":"Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303\u20131310.","journal-title":"Hepatology"},{"key":"6281_CR40","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u20132593.","journal-title":"JAMA"},{"key":"6281_CR41","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","volume":"328","author":"H Tsukuma","year":"1993","unstructured":"Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797\u20131801.","journal-title":"N Engl J Med"},{"key":"6281_CR42","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.510250344","volume":"25","author":"S Bruno","year":"1997","unstructured":"Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754\u2013758.","journal-title":"Hepatology"},{"key":"6281_CR43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174\u2013181.","journal-title":"Ann Intern Med"},{"key":"6281_CR44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00535-010-0293-6","volume":"46","author":"M Tateyama","year":"2011","unstructured":"Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92\u2013100.","journal-title":"J Gastroenterol"},{"key":"6281_CR45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/605947","volume":"200","author":"K Page","year":"2009","unstructured":"Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200:1216\u20131226.","journal-title":"J Infect Dis"},{"key":"6281_CR46","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","volume":"359","author":"SH Mehta","year":"2002","unstructured":"Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478\u20131483.","journal-title":"Lancet"},{"key":"6281_CR47","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.21376","volume":"44","author":"J Grebely","year":"2006","unstructured":"Grebely J, Conway B, Raffa JD, et al. Hepatitis C virus reinfection in injection drug users. Hepatology. 2006;44:1139\u20131145.","journal-title":"Hepatology"},{"key":"6281_CR48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","volume":"138","author":"WO Osburn","year":"2010","unstructured":"Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138:315\u2013324.","journal-title":"Gastroenterology"},{"key":"6281_CR49","doi-asserted-by":"crossref","first-page":"e80216","DOI":"10.1371\/journal.pone.0080216","volume":"8","author":"R Sacks-Davis","year":"2013","unstructured":"Sacks-Davis R, Aitken CK, Higgs P, et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS ONE. 2013;8:e80216.","journal-title":"PLoS ONE"},{"key":"6281_CR50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/cis921","volume":"56","author":"K Page","year":"2013","unstructured":"Page K, Osburn W, Evans J, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis. 2013;56:405\u2013413.","journal-title":"Clin Infect Dis"},{"key":"6281_CR51","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823\u2013830.","journal-title":"J Hepatol"},{"key":"6281_CR52","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1600-6143.2010.03037.x","volume":"10","author":"PJ Thuluvath","year":"2010","unstructured":"Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999\u20132008. Am J Transplant. 2010;10:1003\u20131019.","journal-title":"Am J Transplant"},{"key":"6281_CR53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","volume":"138","author":"GL Davis","year":"2010","unstructured":"Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513\u2013521.","journal-title":"Gastroenterology"},{"key":"6281_CR54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","volume":"50","author":"K Lang","year":"2009","unstructured":"Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89\u201399.","journal-title":"J Hepatol"},{"key":"6281_CR55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","volume":"10","author":"RA Wolfe","year":"2010","unstructured":"Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999\u20132008. Am J Transplant. 2010;10:961\u2013972.","journal-title":"Am J Transplant"},{"key":"6281_CR56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/jgh.13638","volume":"32","author":"AO Lo","year":"2017","unstructured":"Lo AO, Chan HL, Wong VW, et al. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol. 2017;32:1071\u20131078.","journal-title":"J Gastroenterol Hepatol"},{"key":"6281_CR57","doi-asserted-by":"crossref","first-page":"e0155934","DOI":"10.1371\/journal.pone.0155934","volume":"11","author":"GF Chen","year":"2016","unstructured":"Chen GF, Wei L, Chen J, et al. Will sofosbuvir\/ledipasvir (Harvoni) be cost-effective and affordable for Chinese patients infected with hepatitis C virus? An economic analysis using real-world data. PLoS ONE. 2016;11:e0155934.","journal-title":"PLoS ONE"},{"key":"6281_CR58","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","volume":"98","author":"CA Chong","year":"2003","unstructured":"Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98:630\u2013638.","journal-title":"Am J Gastroenterol"},{"key":"6281_CR59","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ajg.2016.99","volume":"111","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Henry L, et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111:808\u2013816.","journal-title":"Am J Gastroenterol"},{"key":"6281_CR60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26:391\u2013400.","journal-title":"Med Decis Mak"},{"key":"6281_CR61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118\u2013124.","journal-title":"Bull World Health Organ"},{"key":"6281_CR62","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s10096-017-2995-7","volume":"36","author":"X Li","year":"2017","unstructured":"Li X, Chan NS, Tam AW, et al. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis. 2017;36:1801\u20131809.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6281_CR63","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u20131103.","journal-title":"JAMA"},{"key":"6281_CR64","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/17474124.2018.1540929","volume":"12","author":"J Puig-Junoy","year":"2018","unstructured":"Puig-Junoy J, Pascual-Argente N, Puig-Codina L, et al. Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol. 2018;12:1251\u20131263.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6281_CR65","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/jgh.13663","volume":"32","author":"HL Chan","year":"2017","unstructured":"Chan HL, Tsang OT, Hui YT, et al. Real-life efficacy and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. J Gastroenterol Hepatol. 2017;32:1230\u20131233.","journal-title":"J Gastroenterol Hepatol"},{"key":"6281_CR66","doi-asserted-by":"crossref","first-page":"43925","DOI":"10.18632\/oncotarget.14937","volume":"8","author":"CF Huang","year":"2017","unstructured":"Huang CF, Yeh ML, Huang CI, et al. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget. 2017;8:43925\u201343933.","journal-title":"Oncotarget"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06281-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:32:32Z","timestamp":1620437552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06281-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6281"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06281-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"6 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"MFY, SHL, WKS, and LYM declare no conflicts of interest. DCH, MYKL, and TKK are employees of Merck Sharp & Dohme (Asia) Ltd. AP is an employee of Merck & Co., Inc. SLC is an employee of Pharmerit International, which received consulting fees from Merck & Co., Inc., for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}